Study of Volrustomig for advanced head and neck cancer after chemoradiation
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma that started in the oropharynx, hypopharynx, oral cavity, or larynx (voice box).
- Your cancer is locally advanced (Stage III, IVA, or IVB) and has not spread to other parts of the body.
- You have not had surgery to remove the tumor (it is 'unresected').
- You have completed a full course of chemoradiation (chemotherapy and radiation given together) with the goal to cure the cancer.
- Your cancer is not a different type (like nasopharyngeal or salivary gland cancer) and you have not had more than one primary tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation therapy only to the side of the neck that needs it, which may reduce side effects while still preventing cancer from coming back. It is for people who have had surgery for head and neck cancer and have not had the cancer spread to the lymph nodes.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
This trial tests a new drug called volrustomig, alone or with other cancer treatments, for people with advanced or metastatic solid tumors. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
This trial tests a new drug called volrustomig, which helps your immune system fight cancer, as a first treatment for advanced non-small cell lung cancer. It's for people whose tumors do not have certain gene changes (like EGFR) that have other targeted treatments available.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.